Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.
Ontology highlight
ABSTRACT: Acquired resistance to chemotherapy is a major limitation in clinical treatment for breast cancer. Accumulating evidence from in vitro, in vivo and clinical studies suggest that acquired chemoresistance is progressive, multifactorial and involve genetic and epigenetic aberrations. Among various mechanisms that contribute to chemoresistance, cellular reprogramming has extensively been implicated in breast cancer resistance lately. Cellular reprogramming events such as acquisition of epithelial to mesenchymal transition (EMT) and cancer stemness (CSCs) not only provide cancer cells with reversible phenotypic plasticity and survival advantage against cytotoxicity but also leads to aggressiveness, metastasis, clinical resistance, tumor recurrence and poor survival. The transient
SUBMITTER: Ponnusamy L
PROVIDER: S-EPMC8992622 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA